Related Experiment Videos
Differential regulation of microglial activation by propentofylline via cAMP signaling
1Department of Physiology, Ehime University School of Medicine, Shigenobu, Ehime, 791-02, Japan.
Abstract:
A pathological microglial activation is believed to contribute to progressive neuronal damage in neurodegenerative diseases by the release of potentially toxic agents and by triggering reactive astrocytic changes. Using cultured microglia from neonatal rat brains, we investigated the mode of propentofylline action in strengthening cAMP-dependent intracellular signaling. We compared this action with the effects of dibutyryl-cAMP, a cell-permeable cAMP analog. Propentofylline inhibited lipopolysaccharide (LPS)-induced release of both tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta in a dose-dependent manner within the therapeutic low micromolar range. However, LPS-induced release of IL-6 and NO were not affected by propentofylline. All these differential effects of propentofylline on LPS-induced microglial release were mimicked by the addition of dibutyryl-cAMP. Microglial proliferation and phorbol myristate acetate (PMA)-induced O2- release were also dose-dependently inhibited by propentofylline as well as dibutyryl-cAMP. These results suggest that propentofylline, probably via reinforcement of cAMP intracellular signaling, alters the profile of the newly adopted immune properties in a way that it inhibits potentially neurotoxic functions while maintaining beneficial functions. This differential regulation of microglial activation may explain the neuroprotective mechanism exerted by propentofylline.
Insights
Propentofylline reduces harmful microglial activation in neurodegenerative diseases by enhancing cAMP signaling. This drug selectively inhibits toxic factor release while preserving beneficial functions, suggesting a neuroprotective mechanism.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Pathological microglial activation contributes to neuronal damage in neurodegenerative diseases.
- Microglia release toxic agents and trigger astrocytic changes, exacerbating neuroinflammation.
- Understanding modulators of microglial activation is crucial for developing neuroprotective therapies.
Purpose of the Study:
- To investigate the mechanism of propentofylline's action on microglial activation.
- To determine if propentofylline strengthens cAMP-dependent intracellular signaling.
- To compare propentofylline's effects with dibutyryl-cAMP, a cAMP analog.
Main Methods:
- Primary microglia cultures from neonatal rat brains were utilized.
- Lipopolysaccharide (LPS) was used to induce microglial activation.
- Propentofylline and dibutyryl-cAMP effects on cytokine release (TNF-alpha, IL-1beta, IL-6), nitric oxide (NO), proliferation, and superoxide anion (O2-) release were measured.
Main Results:
- Propentofylline dose-dependently inhibited LPS-induced TNF-alpha and IL-1beta release.
- LPS-induced IL-6 and NO release were not affected by propentofylline.
- Propentofylline and dibutyryl-cAMP similarly inhibited microglial proliferation and PMA-induced O2- release.
Conclusions:
- Propentofylline reinforces cAMP intracellular signaling in microglia.
- This action selectively inhibits potentially neurotoxic microglial functions.
- Propentofylline's differential regulation of microglial activation suggests a neuroprotective mechanism in neurodegenerative diseases.